vertex
pharmaceuticals
said
thursday
biochem
pharma
started
phase
ii
clinical
trials
vx-710
breast
cancer
soft
tissue
sarcoma.vertex
developing
vx-710
resensitize
tumor
cells
treatment
chemotherapeutic
agents
patients
cancer
complicated
multidrug
resistance.the
company
said
multidrug
resistance
significantly
limits
efficacy
cancer
chemotherapy
regimens
major
factor
failure
cancer
chemotherapy.biochem
vertex
partner
development
marketing
vx-710
canada.the
start
clinical
trials
breast
cancer
soft
tissue
sarcoma
follows
phase
ii
clinical
trial
vx-710
patients
liver
cancer
vertex
began
mid-1996
